Abstract
The recent SARS-CoV-2 outbreak has researchers working tirelessly to understand the virus' pathogenesis and develop an effective vaccine. The urgent need for rapid development and deployment of such a vaccine has illustrated the limitations of current practices, and it has highlighted the need for alternative models for early screening of such technologies. Traditional 2D cell culture does not accurately capture the effects of a physiologically relevant environment as they fail to promote appropriate cell-cell and cell-environment interactions. This inability to capture the intricacies of the in vivo microenvironment prevents 2D cell cultures from demonstrating the necessary properties of native tissues required for the standard infection mechanisms of the virus, thus contributing the high failure rate of drug discovery and vaccine development. 3D cell culture models can bridge the gap between conventional cell culture and in vivo models. Methods such as 3D bioprinting, spheroids, organoids, organ-on-chip platform, and rotating wall vessel bioreactors offer ways to produce physiologically relevant models by mimicking in vivo microarchitecture, chemical gradients, cell–cell interactions and cell–environment interactions. The field of viral biology currently uses 3D cell culture models to understand the interactions between viruses and host cells, which is crucial knowledge for vaccine development. In this review, we discuss how 3D cell culture models have been used to investigate disease pathologies for coronaviruses and other viruses such as Zika Virus, Hepatitis, and Influenza, and how they may apply to drug discovery and vaccine development.
Introduction
Viruses, infectious agents, can only replicate in a host organism (Lodish et al., ). Prior to infection of a host, viruses exist as independent particles called virions. Virions contain nucleic acids, most commonly DNA or RNA, that allow them to mutate and evolve. A coat consisting of proteins or lipids called a capsid protects their genetic material. Viral infection occurs when proteins on the surface of a virion bind to specific receptor proteins on the surface of host cells. After infection, a virus will hijack the machinery of the host cell to produce and release copies of the virus to infect nearby cells. If a person has not encountered this virus before, their immune system undergoes a process to identify these viral particles as being foreign and then remove them from the body. The immune system then retains memory of that virus. A vaccine is a biological agent that elicits a protective immune response targeting a particular pathogen without requiring the host to acquire the disease (Vetter et al., 2018). There are several types of vaccines, each with different ways of inducing different adaptive immune mechanisms. Live-attenuated vaccines are composed of pathogens that have been adapted to be less virulent than the functional virus. Healthy vaccine recipients develop long-term immunity similar to having recovered from the viral infection (Vetter et al., 2018). Inactivated vaccines use deactivated pathogens that are incapable of causing infection. While inactivation destroys the ability of the virus to replicate, its immunogenicity is retained to allow the immune system to target the pathogen. Subunit and conjugate vaccines use select fragments of a pathogen, such as proteins, polysaccharides, or parts of a virus that may form virus-like particles, to incite an immune response. Toxoid vaccines utilize inactivated toxins that, while no longer harmful, preserve their ability to induce toxin-neutralizing antibodies (Vetter et al., 2018). Modern vaccine designs have been introduced to address limitations of current vaccine types. These technologies include nucleic-acid based vaccines that insert DNA or RNA encoded with antigenic proteins into cells, and recombinant vector vaccines use non-pathogenic vectors, such as a virus or bacterium, to introduce the foreign genetic material into cells (Vetter et al., 2018; NIAID, ).
A potential vaccine must be assessed for toxicity, induced immunogenic response, efficacy, and impact on public health while meeting guidelines of regulatory health agencies before being approved for use in humans (Singh and Mehta, 2016). The development process can be divided into the preclinical stages (in vitro and in vivo animal tests) followed by the three clinical stages using human subjects. Only a select few vaccines currently in development will successfully complete the transition from laboratory to clinical trials. The development timeline of vaccines can take anywhere from 5 years at an accelerated rate to upwards of 15 years (Bregu et al., ). It was found that only 16.2% of vaccines were able to advance from preclinical trials to Food and Drug Administration approval in the United States from 2006 to 2015 (Thomas et al., 2016). The associated cost of vaccine development from discovery to licensure can come to billions of dollars (Gouglas et al., ). With over 100 million people and counting diagnosed worldwide, the COVID-19 pandemic has catalyzed an international effort to produce a vaccine aiming to provide immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, resulting in some promising results.
SARS-CoV-2 has affected millions of people globally, resulting in a shift of research toward drug and vaccine development (Draft Landscape of COVID-19 Candidate Vaccines, ). On January 11th, 2020 the genetic sequence of the novel coronavirus was identified, catalyzing the search for a suitable vaccine against the virus (Thanh Le et al., 2020). There are currently 66 candidate vaccines against SARS-CoV-2 in clinical trials, and over 100 in preclinical evaluation (Draft Landscape and Tracker of COVID-19 Candidate Vaccines, ). The use of 2D cell culture can facilitate drug discovery and optimize the vaccine development process. The process of cell culture grows and maintains living cells in an artificial environment. Cell culture has proved useful in understanding the fundamental molecular and physical processes that allow cells to assemble into tissues and organs, how tissues to function, and how tissues respond to diseases and treatment with drugs (Duval et al., ; Kapałczyńska et al., ). Life science research often uses mammalian cell culture as a tool for drug discovery, including manufacturing viral vaccines (Hu, ; Ryan, 2020). In comparison to traditional 2D cell culture systems, three-dimensional (3D) cell culture can serve as a better model system for vaccine development by providing a microenvironment that replicates the physiological setting of real cells, enabling better identification of toxicity and other unwanted issues earlier in drug development (Ravi et al., 2015). 2D cell cultures only partially exhibit the morphology and biochemical behavior necessary for viral infection while being unable to imitate the intricacies of microenvironment of in vivo (Rosellini et al., 2019). These limitations can be addressed by 3D cultures that create a tissue-specific microenvironment that mimics in vivo microarchitecture, oxygen, nutrient and metabolic waste gradients, cell–cell interactions and cell–extracellular matrix (ECM) interactions. 3D cell culture generates physiologically relevant models that can be used for drug discovery and high-throughput screening (Langhans, ), and can thus serve as an alternative technique for studying viral replication, bridging the differences between conventional cell culture and in vivo models (D'Aiuto et al., ; Rosellini et al., 2019). A comparison of studies between 2D cell monolayers and 3D cellular aggregates showed that the latter were better predictors of drug responses in vivo (He et al., ). Such preclinical models can more accurately predict clinical outcomes, saving both time and cost during the vaccine development process (Peng et al., ; Zhu and Ding, 2017; Cairns et al., ; Takayama, 2020). Thus, the substitution of 2D cultures by 3D cultures in drug screening requires swift, robust technologies amenable to analysis in a reliable manner (Zhu and Ding, 2017; Bhowmick et al., ; Cairns et al., ). 3D tissue models can provide insight and understanding into the complex interactions between viruses and their host cells that can be useful in the vaccine development process. 2D and 3D cell culture images are shown in Figure 1 to illustrate the differences between these culture methods. This review will discuss the progress made in the field of viral biology using 3D cell culture methods on various viral infections, such as Zika Virus, Hepatitis, Influenza, and Coronaviruses, as well as outline its potential for the development of viral vaccines with a particular focus on SARS-CoV-2.
Figure 1
3D Cell Culture
3D cell culture can be accomplished by using either a scaffold, cell supporting matrix, or non-scaffold-based culture method (Costa et al.,
Figure 2

Different methods of 3D cell culture, including 3D hydrogels, spheroids, organoids, 3D bioprinted tissues, organ-on-a-chip (OOAC), and rotating wall vessel (RWV) bioreactors.
3D bioprinting is the additive manufacturing of biological structures that allows for the precise recreation of complex tissue microenvironment. The high resolution obtained by 3D bioprinting is due to the layer-by-layer positioning of biological materials, biochemicals and living cells to fabricate tissues structures (Murphy and Atala,
Spheroids are micro-sized cellular aggregates that are widely used in the field of oncology (Ryu et al., 2019). They mimic the characteristics of solid tumors from various cancer types in vitro, making them highly suitable for in vitro oncological drug testing. Liquid overlay, hanging drop, microfluidic-based assembly, and spinner flasks can all be used to produce spheroids. Spheroids simulate the communication between cells and interactions between the cells and the ECM better than 2D cell models (Rosellini et al., 2019; Ryu et al., 2019). Cellular spheroids can overcome limitations related to conventional in vitro systems for viral isolation (Rosellini et al., 2019). The sensitivity and efficiency of isolation of three existing viral species, Adenovirus, CMV, and HSV-1, in 2D have been studied in spheroids composed of susceptible cells (Rosellini et al., 2019; Cairns et al.,
Bioreactors are mechanical devices with the means to influence biological and/or biochemical processes (Plunkett and O'Brien,
While single-cell microfluidics have been instrumental in developing an understanding of the molecular and cellular basis of virus–host interactions, the platform does not allow for the study of cell-to-cell spread of a viral infection (Liu et al.,
Coronaviruses
The scientific and medical communities and vaccine industry are rapidly trying to develop a vaccine to address the recent outbreak of the novel coronavirus SARS-CoV-2. Previous experience with vaccines for H1N1 influenza have highlighted the need for novel design and manufacturing platforms (Tatara, 2020). Coronaviruses, or Orthocoronavirinae, are enveloped viruses with a single-stranded RNA genome. They are generally characterized by five major components: the envelope protein, membrane glycoprotein, spike protein, nucleocapsid protein and a single stranded RNA genome (Tatara, 2020). As a positive single-stranded virus, SARS-CoV-2 replicates in the cytoplasm and does not depend on RNA polymerase for transcription (Tatara, 2020). SARS-CoV-2 is thought to be spread primarily through aerosolized droplets due to coughing, sneezing and talking. The virus primarily affects the epithelial tissue of the lungs and causes acute respiratory distress syndrome in 5–10% of infected individuals (Tatara, 2020). Given the severity of the morbidity and mortality rates associated with SARS-CoV-2, there is an urgent need for a deeper understanding of the viral mechanisms of the virus-host interactions of SARS-CoV-2, and more comprehensive and prompter screening of potential vaccines and other therapeutic strategies.
Although animal models have been instrumental in studying disease and the human lung, given the physiological differences between human and animal lungs, it is unsurprising that animal models cannot effectively model the complete pathophysiology of the human lung. Up to 80% of drug therapies that pass preclinical animal trials fail to treat human diseases during clinical trials (Miller and Spence,
In the study of severe acute respiratory syndrome coronavirus (SARS-CoV-1), Suderman et al. engineered 3D tissue assemblies with a RWV bioreactor as a co-culture of human broncho-tracheal cell lines, with a mesenchymal component as the matrix and human broncho-epithelial cells (BEAS-2B) (Goodwin,
Figure 3

The RWV bioreactor used to engineer 3D tissues for the co-culture of human broncho-tracheal cell lines and human broncho-epithelial cells. (A) Confluent cells grown in 2D are combined with media and microcarrier beads in the bioreactor (B) The RWV was used in other studies to form tissue aggregates. It is kept in continuous rotation to prevent detachment and accumulation of cells at the bottom of the bioreactor. This figure is reprinted under the terms of the Creative Commons Attribution License from Gardner and Herbst-Kralovetz (
In February of 2020, Monteil et al. isolated the SARS-CoV-2 from a sample from patient in Sweden to study therapeutic options for COVID-19 (Monteil et al.,
Figure 4

(A) Vascular capillary organoids imaged using light microscopy (upper) and blood vessel organoids using imaged with immunostaining to detect endothelial cells and pericytes (lower). (B) Viral RNA recovered from organoids at day 3 and 6 after SARS-CoV-2 infection. (C) The supernatant from SARS-CoV-2 infected organoids 6 days after infection were used to infect Vero E6 cells. (D) Effect of hrsACE2 on vascular organoids infected with SARS-CoV-2 after organoids were infected with 106 infectious particles and hrsACE2 for 1 h 3 days after SARS-CoV-2 infection. Results were measured using qPCR. Scale bars are 500 and 50 mm. This figure is reprinted under the terms of the Creative Commons Attribution License from Monteil et al. (
Another useful resource in determining the pathophysiology of coronavirus infections and providing potential for drug screenings are the development of 3D in vitro human engineered lung tissue models. In recent years, primary human lung cells have been cultured into 3D tissue arrangements resembling multiple structures of the human lung. Although many of these models have not been used to study coronaviruses directly, they provide insight into various tissue-engineered technologies can be leveraged to study respiratory viruses and viral infections. For example, a 3D environment of human “bronchospheres” has been developed from a population of primary human bronchiolar epithelial cells (Rock et al., 2009). This in vitro clonal sphere-forming assay isolated mouse basal stem cells and human epithelial tissue and embedded them into a 3D ECM gel (Rock et al., 2009). These experiments looked at cell behavior, primarily regeneration and differentiation, and found that the mouse basal stem cells were capable of self-renewal and generation of differentiated daughter cells. The assays developed in these experiments revealed potential mechanisms that regulate basal cells and allowed for comparison to other epithelial stem cells, they can also facilitate the study of the development, maintenance, and repair of epithelial airways and the mechanisms that regulate them (Rock et al., 2009). Bronchiolar epithelial cells have also been co-cultured with lung microvascular endothelial cells and lung fibroblasts in a 3D culture to create airway organoids (Tan et al., 2018). The study demonstrated that the randomly mixed cell populations underwent rapid self-organization and cell condensation into epithelial and endothelial structures. The structures remained stable and mechanically robust over the long-term culture. Interestingly, despite the proximal source of epithelium, both proximal and distal epithelial properties were observed, demonstrating the high-level plasticity of the organoid. The results demonstrated that the 3D airway organoid culture offers a new tool for the study of lung-based diseases and cell-based therapy (Tan et al., 2018). Biological scaffolds can also be used to generate 3D cell models. These consist of ECM from decellularized rodent and human lungs reseeded with human lung cells (Booth et al.,
Using 3D Culture Models to Study the Influenza A Virus
Influenza is a major cause of death worldwide, claiming between 250,000 and 50,000 lives per year globally (Bhowmick et al.,
A study conducted in 2018 by Bhowmick et al. marked the first step in designing and creating a complete 3D-Human Tissue-Engineering Lung Model (3D-HTLM) (Bhowmick et al.,
Figure 5

3D tissue engineering lung model and comparative analysis of 2D and 3D culturing of HSAEpCs (A) 3D culturing of HSAEpCs on chitosan-collagen scaffolds. (B) 2D culturing of HSAEpCs on membrane inserts. (C) SEM images showing the thickness (i) and pores (ii) of the chitosan-collagen scaffolds. (D) Cell viability of HSAEpCs from 2D and 3D culturing. This figure is reprinted under the terms of the Creative Commons Attribution License from Bhowmick et al. (
Another study performed in 2018 by Berg et al. looked at how efficiently different 3D bioprinted cultures were infected by IAV and compared the results to a natural lung and a conventional 2D cell culture model (Berg et al.,
Figure 6

3D printed cultures of A549 cells. (A) Various shapes of constructs made through extrusion printing. (B) Illustration of 3D printing setup. (C) Viscosity of uncrosslinked bioinks at a shear rate sweep of 1–100 s−1 at 24°C. (D) Storage and loss modulus of bioink formulas at 1 Hz, 24°C, and 1% shear strain after the addition of CaSO4. This figure is reprinted under the terms of the Creative Commons Attribution License from Berg et al. (
Using 3D Culture Models to Study the Zika Virus
Since the effects of SARS-CoV-2 fetal development and the brain are still being researched, the ZIKV study models can be directly translated to study the effects of SARS-CoV-2 infection in the brain, pregnancies, and fetal development. During pregnancy, hormonal levels and immune system function are changed to reduce the potential of fetal rejection, allowing fetal development. This causes higher mortality rates and complications due to viral infection in pregnant women compared to the general population (Alberca et al.,
In 2016, Tang et al. linked ZIKV exposure to microcephaly by confirming its inhibitory action in the formation and growth of Neuronal Progenitor Cells (NPCs) derived from induced Pluripotent Stem Cells (iPSCs) in 2D cell cultures (Hengli Tang et al.,
Figure 7

(A) Design of spinning bioreactor used to produce brain organoids. (B) diagram of the organoid protocol and images at the different stages of development (scale bars are 200 mm). (C,D) Organoids after immunostaining (scale bars are 100 mm). This figure is reprinted under the terms of the Creative Commons Attribution License from Qian et al. (
Although 3D culture techniques have greatly improved when accurately recapitulating in vivo cell-cell and cell-extracellular matrix interactions by more closely approximating living tissue, generation and study of complex and organized structures has remained difficult until recent technological advancements. The most prominent challenges with prior methods involve the death of inner cells in larger organoids due to the lack of vascularization (blood vessel formation) (Zhuang et al., 2018). Spinning bioreactors facilitate better nutrient exchange, which allows for organoids up to a few millimeters in size. Accordingly, Takebe et al. (2013) demonstrated that co-culture with endothelial cells can create vascular-like networks, but more progress is needed for the creation of viable organoids of significant size or complexity. While the issue of vascularization has not yet been solved for creating large brain organoids, methods have been proposed to address this deficiency. Bioinks can be infused with multicellular aggregates called spheroids that are formed either through spontaneous self-arrangement or forced cell adhesion without scaffolds. Spheroids can be adapted to more accurately recapitulate human brain features such a cell diversity, electrical properties and mechanical stiffness (Zhuang et al., 2018). Hsu et al. used spheroids composed of neural and vascular progenitor cells formed by the chitosan (CS)-based substrates or other methods. The resulting co-spheroids are suspended in growth factors and an appropriate bioink for both types of progenitor cells and can be printed using available methods (Han and Hsu,
In other work developing 3D models of brain tissues, Kador et al. developed a technique in 2016 to construct 3D printed scaffolds from electrospun polylactic acid (PLA) nanofibers suspended in hydrogel to guide the formation of retinal ganglion cell structures (Kador et al.,
Many existing studies focus on clinical outcomes or therapeutics, few consider viral transmission or mobility. 3D bioprinting and organoid cultures have the potential to produce more accurate models of biological interfaces. In the case of ZIKV, the contagion must cross a maternal-fetal interface which is most commonly the blood-placenta barrier or BPB, although intrauterine transmission is also possible, with ZIKV having been detected in the amniotic fluid of effected pregnancies (Costa,
Figure 8

A model of the BPB, and the system used to culture BeWO b30 and HUVEC cells to perform a transport assay. (A) A diagram of the maternal decidua, along with the (B) maternal side and the (C) maternal-fetal interface. A (D) diagram and (E) image of the BPB model used. (F) A timeline of culturing BeWo b30 cells (day 0) and HUVEC cells (day 7) before the performed assays (day 10). (G) Schematic transport assay, (H,I) plug used in transwell insert, (J) transwell insert, and (K) image of transport assay. This figure is reprinted under the terms of the Creative Commons Attribution License from Arumugasaamy et al. (
Using 3D Culture Models to Study the Hepatitis Virus
Hepatitis often refers to an inflamed liver. It can be caused by several factors, most notably, alcohol abuse and Viral Hepatitis. The five types of viral hepatitis are Hepatitis A, B, C, D, and E virus (HAV, HBV, HCV HDV, HEV). The World Health Organization estimates that 325 million people worldwide live with HBV or HCV (Hepatitis,
The production of 3D hepatic structures to more closely mimic in vivo conditions is often sought for potential transplants. Recent advances in 3D bioprinting of liver models showed promising results and possibilities for future viral treatment and testing. A 2018 study by Mazzocchi et al. (
Figure 9

3D microfluidic system with primary human hepatocytes cultured in a bioreactor. (A) Illustration of the bioreactor showing continuous pumping of media and a collagen-coated scaffold. (B) Cell viability 13 days after seeding 3D cultures. (C) Comparison of the various cell cultures: 2D hepatocytes, 3D spheroids, hepatic and mouse fibroblasts (SACC PHH), and 3D hepatocytes. (D) Immunofluorescence of cell cultures 14 days after seeding. (E) Albumin secretion from cultures 14 days after seeding from ELISA. White scale bars are 200 mm and gray scale bars are 500 mm. This figure is reprinted under the terms of the Creative Commons Attribution License from Ortega-Prieto et al. (
Conclusion
Modeling biological systems in vitro remains a difficult task, built on reducing complexity so that the effect of various conditions can be observed, while replicating in vivo morphology and biochemistry in a meaningful way. This review illustrates the benefits of using 3D tissue culture techniques over 2D tissue culture when studying viral infections and the implications with regards to studying COVID-19. Techniques like spheroid cultures and organoids have been shown to replicate systems of viral infection more accurately than 2D cultures and to produce morphology and biochemical behaviors required to allow for viral infection in cases where 2D cultures do not. Bioprinting and OOAC allow for high throughput drug screening and antibody testing on systems that more accurately replicate human tissue than 2D counterparts.
3D culture methods, however, are not without their limitations. The greatest concern with 3D tissue models for the purpose of drug and vaccine development remains to be the ability of the culture model to fully embody the biological, chemical, and physical microenvironmental parameters that mimic in-vivo tissue and disease pathology. Spheroids cultures have been known to exhibit hypoxia and necrosis at their core. The incorporation of spheroids into a microfluidic system that is oxygen and growth factor-permeable can mitigate these limitations (Ryu et al., 2019). The use of an OOAC microfluidic system can mitigate these limitations while also providing a physiologically relevant microenvironment.
Similarly, the incorporation of a rotating or spinning vessel, such as the RWV bioreactor, can help provide the necessary oxygenation and nutrients for development and polarization as described previously. Organoid cultures are typically formed with only the epithelial layer and lack the surrounding tissue microenvironment. Due to this, organoids as well as spheroids lack tissue-tissue interactions, limiting their functionality. This can be addressed by conducting more extensive studies on organoid co-culture systems. Organoid cultures are also commonly dependent on the use of batch-varying xeno-derived ECM or basement membrane, making them that are inapt for human drug studies (Xu et al., 2018). However, there is great potential in the field of personalized medicine for patient-derived organoids to provide robust personalized data, including patient-specific mutation profiles and drug responses (Kim et al.,
Moreover, streamlined processes have not been established for culture methods, which can result in variability within studies especially in regard to high throughput and high content screening. There is also a lack of automated imaging techniques of 3D cultures that provide satisfactory images. The size of 3D constructs, material transparency, and depth of microscopes available all limit the ability to achieve clear, representative images (Anton et al.,
Statements
Author contributions
NL, CP, CS, LA, IF, RS, RK, and MH contributed to the writing of the initial draft. IF, LA, EA, and SW edited and formatted the draft for submission. All authors contributed to the article and approved the submitted version.
Funding
This project funded with support from TechNation wage subsidy program, Coast Capital Savings, Innovate B.C co-op program, NSERC Discovery Grant program, the Alzheimer's Association, Canada Research Chairs and the Michael Smith Foundation for Health Research and Pacific Parkinson's Research Institute's Innovation to Commercialization grant.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AdcockR. S.ChuY. K.GoldenJ. E.ChungD. H. (2017). Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay. Antiviral Res. 138, 47–56. 10.1016/j.antiviral.2016.11.018
2
AgumaduV. C.RamphulK. (2018). Zika virus: a review of literature. Cureus. 10:e3025. 10.7759/cureus.3025
3
AlbercaR. W.PereiraN. Z.OliveiraL. M. D. S.Gozzi-SilvaS. C.SatoM. N. (2020). Pregnancy, viral infection, and COVID-19. Front. Immunol. 11:1672. 10.3389/fimmu.2020.01672
4
AndradeC. F.WongA. P.WaddellT. K.KeshavjeeS.LiuM. (2007). Cell-based tissue engineering for lung regeneration. Am. J. Physiol. Lung Cell. Mol. Physiol. 292, 510–518. 10.1152/ajplung.00175.2006
5
Antill-O'BrienN.BourkeJ.O'ConnellC. D. (2019). Layer-by-layer: the case for 3D bioprinting neurons to create patient-specific epilepsy models. Materials12:3218. 10.3390/ma12193218
6
AntonD.BurckelH.JossetE.NoelG. (2015). Three-dimensional cell culture: a breakthrough in vivo. Int. J. Mol. Sci. 16, 5517–5527. 10.3390/ijms16035517
7
ArumugasaamyN.EttehadiehL. E.KuoC. Y.Paquin-ProulxD.KitchenS. M.SantoroM.et al. (2018). Biomimetic placenta-fetus model demonstrating maternal–fetal transmission and fetal neural toxicity of Zika virus. Ann. Biomed. Eng. 46, 1963–1974. 10.1007/s10439-018-2090-y
8
BahramM.MohseniN.MoghtaderM. (2016). Introduction to hydrogels and some recent applications, in In Emerging Concepts in Analysis and Applications of Hydrogels, eds Majee, S. B. (London: InTech).
9
BaigA. M.KhaleeqA.AliU.SyedaH. (2020). Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem. Neurosci. 11, 995–998. 10.1021/acschemneuro.0c00122
10
BergJ.HillerT.KissnerM. S.QaziT. H.DudaG. N.HockeA. C.et al. (2018). Optimization of cell-laden bioinks for 3D bioprinting and efficient infection with influenza A virus. Sci. Rep. 8, 1–13. 10.1038/s41598-018-31880-x
11
BhowmickR.DerakhshanT.LiangY.RitcheyJ.LiuL.Gappa-FahlenkampH. (2018). A three-dimensional human tissue-engineered lung model to study influenza a infection. Tissue Eng. Part A24, 1468–1480. 10.1089/ten.tea.2017.0449
12
BlundellC.TessE. R.SchanzerA. S. R.CoutifarisC.SuE. J.ParryS.et al. (2016). A microphysiological model of the human placental barrier. Lab Chip16, 3065–3073. 10.1039/C6LC00259E
13
BoothA. J.HadleyR.CornettA. M.DreffsA. A.MatthesS. A.TsuiJ. L.et al. (2012). Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am. J. Respir. Crit. Care Med. 186, 866–876. 10.1164/rccm.201204-0754OC
14
BouvierN. M.PaleseP. (2008). The biology of influenza viruses. Vaccine26, 49–53. 10.1016/j.vaccine.2008.07.039
15
BreguM.DraperS. J.HillA. V. S.GreenwoodB. M. (2011). Accelerating vaccine development and deployment: report of a Royal Society satellite meeting. Philos. Trans. R. Soc. B Biol. Sci. 366, 2841–2849. 10.1098/rstb.2011.0100
16
BreslinS.O'DriscollL. (2016). The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance. Oncotarget7, 45745–45756. 10.18632/oncotarget.9935
17
CairnsD. M.RouleauN.ParkerR. N.WalshK. G.GehrkeL.KaplanD. L. (2020). A 3D human brain–like tissue model of herpes-induced Alzheimer's disease. Sci. Adv. 6:eaay8828. 10.1126/sciadv.aay8828
18
CDC (2021). Summary of Progress since 2009 | Pandemic Influenza (Flu). CDC. Available online at: https://www.cdc.gov/flu/pandemic-resources/h1n1-summary.htm (accessed February 14, 2021).
19
CentenoE. G. Z.CimarostiH.BithellA. (2018). 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling. Mol. Neurodegener.13:27. 10.1186/s13024-018-0258-4
20
ChanJ. F. W.YipC. C. Y.TsangJ. O. L.TeeK. M.CaiJ. P.ChikK. K. H.et al. (2016). Differential cell line susceptibility to the emerging Zika virus: implications for disease pathogenesis, non-vector-borne human transmission and animal reservoirs. Emerg. Microbes Infect. 5:e93. 10.1038/emi.2016.99
21
ChengQ.YangY.GaoJ. (2020). Infectivity of human coronavirus in the brain. EBioMedicine56:102799. 10.1016/j.ebiom.2020.102799
22
CortiellaJ.NicholsJ. E.KojimaK.BonassarL. J.DargonP.RoyA. K.et al. (2006). Tissue-engineered lung: an in vivo and in vitro comparison of polyglycolic acid and pluronic F-127 hydrogel/somatic lung progenitor cell constructs to support tissue growth. Tissue Eng. 12, 1213–1225. 10.1089/ten.2006.12.1213
23
CostaE. C.MoreiraA. F.de Melo-DiogoD.GasparV. M.CarvalhoM. P.CorreiaI. J. (2016). 3D tumor spheroids: an overview on the tools and techniques used for their analysis. Biotechnol. Adv.34, 1427–1441. 10.1016/j.biotechadv.2016.11.002
24
CostaM. A. (2016). The endocrine function of human placenta: an overview. Reprod. Biomed. Online32, 14–43. 10.1016/j.rbmo.2015.10.005
25
D'AiutoL.NaciriJ.RadioN.TekurS.ClaytonD.ApodacaG.et al. (2018). Generation of three-dimensional human neuronal cultures: application to modeling CNS viral infections. Stem Cell Res. Ther. 9:134. 10.1186/s13287-018-0881-6
26
DangJ.TiwariS. K.LichinchiG.QinY.PatilV. S.EroshkinA. M.et al. (2016). Zika virus depletes neural progenitors in human cerebral organoids through activation of the innate immune receptor TLR3. Cell Stem Cell19, 258–265. 10.1016/j.stem.2016.04.014
27
de la VegaL.LeeC.SharmaR.AmerehM.WillerthS. M. (2019). 3D bioprinting models of neural tissues: the current state of the field and future directions. Brain Res. Bull.150, 240–249. 10.1016/j.brainresbull.2019.06.007
28
DosSantosM. F.DevalleS.AranV.CapraD.RoqueN. R.Coelho-AguiarJ.et al. (2020). Neuromechanisms of SARS-CoV-2: A Review. Front. Neuroanat. 14:37. 10.3389/fnana.2020.00037
29
Draft Landscape of COVID-19 Candidate Vaccines - 9 June 2020 (2020). World Heatlh Organization.
30
Draft Landscape Tracker of COVID-19 Candidate Vaccines. (2021). Available online at: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed February 15, 2021).
31
DuvalK.GroverH.HanL. H.MouY.PegoraroA. F.FredbergJ.et al. (2017). Modeling physiological events in 2D vs. 3D cell culture. Physiology32, 266–277. 10.1152/physiol.00036.2016
32
GardnerJ. K.Herbst-KralovetzM. M. (2016). Three-dimensional rotating wall vessel-derived cell culture models for studying virus-host interactions. Viruses8:304. 10.3390/v8110304
33
GilpinS. E.OttH. C. (2015). Using nature's platform to engineer bio-artificial lungs. Ann. Am. Thorac. Soc. 12, S45–S49. 10.1513/AnnalsATS.201408-366MG
34
GoodwinT. J. (2006). Three-Dimensional Human Bronchial-Tracheal Epithelial Tissue-Like Assemblies (TLAs) as Hosts for Severe Acute Respiratory Syndrome (SARS)-CoV Infection SARS-CoV Infection in a 3-D HBTE Tissue-Like Assembly, NASA Technical Paper.
35
GouglasD.Thanh LeT.HendersonK.KaloudisA.DanielsenT.HammerslandN. C.et al. (2018). Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Lancet Glob. Heal. 6, e1386–e1396. 10.1016/S2214-109X(18)30346-2
36
HanH. W.HsuS. H. (2017). Using 3D bioprinting to produce mini-brain. Neural Regen. Res. 12, 1595–1596. 10.4103/1673-5374.217325
37
HeB.ChenG.ZengY. (2016). Three-dimensional cell culture models for investigating human viruses. Virol. Sin. 31, 363–379. 10.1007/s12250-016-3889-z
38
Hengli TangA.HammackC.OgdenS. C.JinP.SongH.MingG. (2016). Zika virus infects human cortical neural progenitors and attenuates their growth. Cell Stem Cell18, 587–590. 10.1016/j.stem.2016.02.016
39
Hepatitis. (2020). Available online at: https://www.who.int/health-topics/hepatitis#tab=tab_1 (accessed October 4, 2020).
40
HillerT.BergJ.ElomaaL.RöhrsV.UllahI.SchaarK.et al. (2018). Generation of a 3D liver model comprising human extracellular matrix in an alginate/gelatin-based bioink by extrusion bioprinting for infection and transduction studies. Int. J. Mol. Sci. 19:3129. 10.3390/ijms19103129
41
HoffmannM.Kleine-WeberH.SchroederS.KrügerN.HerrlerT.ErichsenS.et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell181, 271–280.e8. 10.1016/j.cell.2020.02.052
42
HuW.-S. (2020). Overview of cell culture processes, in Cell Culture Bioprocess Engineering (Boca Raton: CRC Press), 1–35.
43
JeonH.KangK.ParkS. A.KimW. D.PaikS. S.LeeS. H.et al. (2017). Generation of multilayered 3D structures of HepG2 cells using a bio-printing technique. Gut Liver11, 121–128. 10.5009/gnl16010
44
JohansenL. M.DeWaldL. E.ShoemakerC. J.HoffstromB. G.Lear-RooneyC. M.StosselA.et al. (2015). A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci. Transl. Med. 7:290ra89. 10.1126/scitranslmed.aaa5597
45
JohnsonC. D.AmatoA. R. D.'PuhlD. L. (2014). Patterned and functionalized nanofiber scaffolds in three-dimensional hydrogel constructs enhance neurite outgrowth and directional control. J. Nueral Eng. 11:066009. 10.1088/1741-2560/11/6/066009
46
KadorK. E.GroganS. P.Dorth,éE. W.VenugopalanP.MalekM. F.GoldbergJ. L.et al. (2016). Control of retinal ganglion cell positioning and neurite growth: combining 3D printing with radial electrospun scaffolds. Tissue Eng. Part A22, 286–294. 10.1089/ten.tea.2015.0373
47
KapałczyńskaM.KolendaT.PrzybyłaW.ZajaczkowskaM.TeresiakA.FilasV.et al. (2018). 2D and 3D cell cultures – a comparison of different types of cancer cell cultures. Arch. Med. Sci.14, 910–919. 10.5114/aoms.2016.63743
48
KimJ.KooB. K.KnoblichJ. A. (2020). Human organoids: model systems for human biology and medicine. Nat. Rev. Mol. Cell Biol. 21, 571–584. 10.1038/s41580-020-0259-3
49
LancasterM. A.RennerM.MartinC. A.WenzelD.BicknellL. S.HurlesM. E.et al. (2013). Cerebral organoids model human brain development and microcephaly. Nature501, 373–379. 10.1038/nature12517
50
LanghansS. A. (2018). Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front. Pharmacol. 9:6. 10.3389/fphar.2018.00006
51
LiuW.HeH.ZhengS. Y. (2020). Microfluidics in single-cell virology: technologies and applications. Trends Biotechnol. 38, 1360–1372. 10.1016/j.tibtech.2020.04.010
52
LodishH.BerkA.ZipurskyS. L.MatsudairaP.BaltimoreD.DarnellJ. (2000). Viruses: Structure, Function, and Uses, New York, NY: WH Freeman.
53
MartinI.WendtD.HebererM. (2004). The role of bioreactors in tissue engineering. Trends Biotechnol. 22, 80–86. 10.1016/j.tibtech.2003.12.001
54
MazzocchiA.DevarasettyM.HuntworkR.SokerS.SkardalA. (2019). Optimization of collagen type I-hyaluronan hybrid bioink for 3D bioprinted liver microenvironments. Biofabrication11:15003. 10.1088/1758-5090/aae543
55
MenesesJ. D. A.IshigamiA. C.De MelloL. M.De AlbuquerqueL. L.De BritoC. A. A.CordeiroM. T.et al. (2017). Lessons learned at the epicenter of Brazil's congenital Zika epidemic: evidence from 87 confirmed cases. Clin. Infect. Dis. 64, 1302–1308. 10.1093/cid/cix166
56
MillerA. J.SpenceJ. R. (2017). In vitro models to study human lung development, disease and homeostasis. Physiology32, 246–260. 10.1152/physiol.00041.2016
57
MinerJ. J.CaoB.GoveroJ.SmithA. M.FernandezE.CabreraO. H.et al. (2016). Zika virus infection during pregnancy in mice causes placental damage and fetal demise. Cell165, 1081–1091. 10.1016/j.cell.2016.05.008
58
MondrinosM. J.KoutzakiS.LelkesP. I.FinckC. M. (2007). A tissue-engineered model of fetal distal lung tissue. Am. J. Physiol. Lung Cell. Mol. Physiol. 293, 639–650. 10.1152/ajplung.00403.2006
59
MonteilV.KwonH.PradoP.HagelkrüysA.WimmerR. A.StahlM.et al. (2020). Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell181, 905–913.e7. 10.1016/j.cell.2020.04.004
60
MurphyS. V.AtalaA. (2014). 3D bioprinting of tissues and organs. Nat. Biotechnol.32, 773–785. 10.1038/nbt.2958
61
MussoD.NillesE. J.Cao-LormeauV. M. (2014). Rapid spread of emerging Zika virus in the Pacific area. Clin. Microbiol. Infect. 20, O595–O596. 10.1111/1469-0691.12707
62
NguyenD. G.FunkJ.RobbinsJ. B.Crogan-GrundyC.PresnellS. C.SingerT.et al. (2016). Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro. PLoS ONE11:e0158674. 10.1371/journal.pone.0158674
63
NiW.YangX.YangD.BaoJ.LiR.XiaoY.et al. (2020). Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit. Care24:422. 10.1186/s13054-020-03120-0
64
NIAID (2020). Vaccine Types | NIH: National Institute of Allergy and Infectious Diseases. Available online at: https://www.niaid.nih.gov/research/vaccine-types (accessed August 23, 2020).
65
NieY. Z.ZhengY. W.MiyakawaK.MurataS.ZhangR. R.SekineK.et al. (2018). Recapitulation of hepatitis B virus–host interactions in liver organoids from human induced pluripotent stem cells. EBioMedicine35, 114–123. 10.1016/j.ebiom.2018.08.014
66
Ortega-PrietoA. M.SkeltonJ. K.WaiS. N.LargeE.LussignolM.Vizcay-BarrenaG.et al. (2018). 3D microfluidic liver cultures as a physiological preclinical tool for hepatitis B virus infection. Nat. Commun. 9:682. 10.1038/s41467-018-02969-8
67
OzbolatI. T. (2015). Bioprinting scale-up tissue and organ constructs for transplantation. Trends Biotechnol. 33, 395–400. 10.1016/j.tibtech.2015.04.005
68
PengW.DattaP.AyanB.OzbolatV.SosnoskiD.OzbolatI. T. (2017). 3D bioprinting for drug discovery and development in pharmaceutics. Acta Biomater.57, 26–46. 10.1016/j.actbio.2017.05.025
69
PlunkettN.O'BrienF. J. (2011). Bioreactors in tissue engineering. Technol. Heal. Care19, 55–69. 10.3233/THC-2011-0605
70
QianX.NguyenH. N.SongM. M.HadionoC.OgdenS. C.HammackC.et al. (2016). Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. Cell165, 1238–1254. 10.1016/j.cell.2016.04.032
71
RadiganK. A.MisharinA. V.ChiM.BudingerG. R. S. (2015). Modeling human influenza infection in the laboratory. Infect. Drug Resist. 8, 311–320. 10.2147/IDR.S58551
72
RaviM.ParameshV.KaviyaS. R.AnuradhaE.Paul SolomonF. D. (2015). 3D cell culture systems: advantages and applications. J. Cell. Physiol.230, 16–26. 10.1002/jcp.24683
73
RockJ. R.OnaitisM. W.RawlinsE. L.LuY.ClarkC. P.XueY.et al. (2009). Basal cells as stem cells of the mouse trachea and human airway epithelium. Proc. Natl. Acad. Sci. U. S. A. 106, 12771–12775. 10.1073/pnas.0906850106
74
RoselliniA.FreerG.QuarantaP.DovereV.MenichiniM.MaggiF.et al. (2019). Enhanced in vitro virus expression using 3-dimensional cell culture spheroids for infection. J. Virol. Methods265, 99–104. 10.1016/j.jviromet.2018.12.017
75
RossiG.ManfrinA.LutolfM. P. (2018). Progress and potential in organoid research. Nat. Rev. Genet. 19, 671–687. 10.1038/s41576-018-0051-9
76
RuedingerF.LavrentievaA.BlumeC.PepelanovaI.ScheperT. (2015). Hydrogels for 3D mammalian cell culture: a starting guide for laboratory practice. Appl. Microbiol. Biotechnol. 99, 623–636. 10.1007/s00253-014-6253-y
77
RyanJ. A. (2020). Introduction to Animal Cell Culture. Available online at: https://www.corning.com/catalog/cls/documents/application-notes/CLS-AN-042.pdf (accessed August 20, 2020).
78
RyuN. E.LeeS. H.ParkH. (2019). Spheroid culture system methods and applications for mesenchymal stem cells. Cells8, 1–13. 10.3390/cells8121620
79
SimpsonC.LeeS. S.LeeC. S.YamauchiY. (2018). Microfluidics: an untapped resource in viral diagnostics and viral cell biology. Curr. Clin. Microbiol. Rep. 5, 245–251. 10.1007/s40588-018-0105-y
80
SinghK.MehtaS. (2016). The clinical development process for a novel preventive vaccine: an overview. J. Postgrad. Med. 62:4. 10.4103/0022-3859.173187
81
TakayamaK. (2020). Trends in pharmacological sciences in vitro and animal models for SARS-CoV- 2 research trends in pharmacological sciences. Trends Pharmacol. Sci. 41, 513–517. 10.1016/j.tips.2020.05.005
82
TakebeT.SekineK.EnomuraM.KoikeH.KimuraM.OgaeriT.et al. (2013). Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature499, 481–484. 10.1038/nature12271
83
TanQ.ChoiK. M.SicardD.TschumperlinD. J. (2018). Human airway organoid engineering as a step toward lung regeneration and disease modeling. Biomaterials113, 118–132. 10.1016/j.biomaterials.2016.10.046
84
TangH.AbouleilaY.SiL.Ortega-PrietoA. M.MummeryC. L.IngberD. E.et al. (2020). Human organs-on-chips for virology. Trends Microbiol. 28, 934–946. 10.1016/j.tim.2020.06.005
85
TataraA. M. (2020). Role of tissue engineering in COVID-19 and future viral outbreaks. Tissue Eng. Part A6, 468–474. 10.1089/ten.tea.2020.0094
86
Thanh LeT.AndreadakisZ.KumarA.Gómez RománR.TollefsenS.SavilleM.et al. (2020). The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 19, 305–306. 10.1038/d41573-020-00151-8
87
ThomasD.BurnsJ.AudetteJ.AnalysisA. C. (2016). Clinical Development Success Rates 2006–2015. The Biotechnology Innovation Organization.
88
TibbittM. W.AnsethK. S. (2009). Hydrogels as extracellular matrix mimics for 3D cell culture. Biotechnol. Bioeng. 103, 655–663. 10.1002/bit.22361
89
VetterV.DenizerG.FriedlandL. R.KrishnanJ.ShapiroM. (2018). Understanding modern-day vaccines: what you need to know. Ann. Med. 50, 110–120. 10.1080/07853890.2017.1407035
90
WuQ.LiuJ.WangX.FengL.WuJ.ZhuX.et al. (2020). Organ-on-a-chip: recent breakthroughs and future prospects. Biomed. Eng. Online19, 1–19. 10.1186/s12938-020-0752-0
91
XuH.JiaoY.QinS.ZhaoW.ChuQ.WuK. (2018). Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine. Exp. Hematol. Oncol. 7:30. 10.1186/s40164-018-0122-9
92
YinX.MeadB. E.SafaeeH.LangerR.KarpJ. M.LevyO. (2016). Engineering stem cell organoids. Cell Stem Cell18, 25–38. 10.1016/j.stem.2015.12.005
93
ZhangB.KoroljA.LaiB. F. L.RadisicM. (2018). Advances in organ-on-a-chip engineering. Nat. Rev. Mater. 3, 257–278. 10.1038/s41578-018-0034-7
94
ZhangZ.XuH.MazzaG.ZhangM.FrenguelliL.LiuQ.et al. (2019). Decellularized human liver scaffold-based three-dimensional culture system facilitate hepatitis B virus infection. J. Biomed. Mater. Res. Part A107, 1744–1753. 10.1002/jbm.a.36690
95
ZhuX.DingX. (2017). Study on a 3D hydrogel-based culture model for characterizing growth of fibroblasts under viral infection and drug treatment. SLAS Discov. 22, 626–634. 10.1177/2472555217701247
96
ZhuangP.SunA. X.AnJ.ChuaC. K.ChewS. Y. (2018). 3D neural tissue models: from spheroids to bioprinting. Biomaterials154, 113–133. 10.1016/j.biomaterials.2017.10.002
97
ZieglerC. G. K.AllonS. J.NyquistS. K.MbanoI. M.MiaoV. N.TzouanasC. N.et al. (2020). SARS-CoV-2 receptor ACE2 Is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell181, 1016–1035.e19. 10.1016/j.cell.2020.04.035
Summary
Keywords
COVID-19, biomaterials, tissue engineering, organoids, antigen, microenvironment
Citation
Lawko N, Plaskasovitis C, Stokes C, Abelseth L, Fraser I, Sharma R, Kirsch R, Hasan M, Abelseth E and Willerth SM (2021) 3D Tissue Models as an Effective Tool for Studying Viruses and Vaccine Development. Front. Mater. 8:631373. doi: 10.3389/fmats.2021.631373
Received
19 November 2020
Accepted
01 March 2021
Published
22 March 2021
Volume
8 - 2021
Edited by
Weihua Li, University of Wollongong, Australia
Reviewed by
Martin Stelzle, University of Tübingen, Germany; Pinar Yilgor Huri, Ankara University, Turkey
Updates

Check for updates
Copyright
© 2021 Lawko, Plaskasovitis, Stokes, Abelseth, Fraser, Sharma, Kirsch, Hasan, Abelseth and Willerth.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Stephanie M. Willerth willerth@uvic.ca
This article was submitted to Biomaterials, a section of the journal Frontiers in Materials
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.